News |

As more dermatology clinicians find themselves increasingly exhausted, being in a hurry can lead to legal repercussions.

The FDA’s PDUFA target date is May 25, 2024.

Ted Lain, MD, MBA, moderated a discussion to share strategies to optimize treatment sequencing, reevaluate long-term management, understand barriers to novel therapies, promote prior authorization integration, and diversify treatment areas.

This article compares physicians in general to average US investors in several key areas and examines how these factors affect a dermatologist’s approach to investing and wealth management.

In this week’s Pointers With Portela, the 208SkinDoc reviews on his podcast why it's dangerous to have moles lasered off before taking a biopsy.

Keep up with the latest headlines in dermatology from the past week, including new research related to eczema and itch linked to bacteria, a new drug developed for melanoma and lung cancer demonstrating potential in the treatment of cSCC, and more.

Experts discuss enhancing patient outcomes, comparing clobetasol cream concentrations, and more.

Recently, a significant breakthrough was achieved when 42 international vitiligo experts and 4 patient representatives collaborated and developed a consensus management strategy for vitiligo.

Audrey Dean’s case highlights the significance of tailoring treatments to individual patient needs, acknowledging that what works for one person might not work for another.

ICYMI, this week we had articles about KT-474 efficacy in atopic dermatitis and hidradenitis suppurativa, endoscopic thoracic sympathectomy surgery for hyperhidrosis, and new data on rademikibart for atopic dermatitis.

The study found that white patients were offered access to patient portals more frequently than Black or Hispanic patients.

Click here to answer this week's poll for Hyperhidrosis Awareness Month.

Because of the chronic inflammatory state of psoriasis and the immunosuppression produced by some systemic medications, patients with psoriasis may have an increased risk of lymphoma and nonmelanoma skin cancer.

One notable change: CVS Caremark has removed the Humira biosimilar Amjevita and now prefers Hyrimoz and an unbranded biosimilar.

Connect Biopharma announced positive long-term data from its China pivotal trial.

Patients with AD and a comorbid allergic condition achieved the same efficacy endpoints as patients without allergic conditions in a study.

Patient Cole Villaflor, his mother, and Michael Levy, MD, PhD, provide insights into Cole’s hyperhidrosis diagnosis and subsequent endoscopic thoracic sympathectomy surgery.

From the November cover: Raj Chovatiya, MD, PhD, and Lawrence Eichenfield, MD, shared their insights and key treatment pearls into atopic dermatitis management for adults and children.

Experts discuss enhancing patient outcomes, topical formulations and epidermal barrier dysfunction, and more.

The newest source of growth factors is from donor tissue.

Immunotherapies, including PD-1 checkpoint inhibitors such as nivolumab, have improved the treatment options for patients with advanced melanoma.

Atoosa Kourosh, MD, MPH, delves into opportunities for allergists and dermatologists to collaborate, her approach to cases, and patient resources.

Jared Gollob, MD, Chief Medical Officer of Kymera Therapeutics, spoke with Dermatology Times to discuss these trial results.

This week’s collection of the latest dermatologic studies covers the relationship between melanoma pigmentation and inflammatory cytokines, the negative use of topical nystatin for tinea infections, the association between psoriasis and schizophrenia, and the association between pediatric atopic dermatitis and cardiovascular risk factors.

Keep up with the latest headlines in dermatology from the past week, including research revealing the presence of hemoglobin in the epidermis, 3D bioprinting to create hair follicles in human skin tissue, and more.

ICYMI, this week we had articles about coverage from the American College of Allergy, Asthma and Immunology 2023 Annual Scientific Meeting, the availability of UCB's bimekizumab, FDA breakthrough therapy designation to QTORIN rapamycin for microcystic lymphatic malformations, and more.

Kwatra presented on the unmet need for itch improvement in patients with skin of color.

Jorge Garcia-Zuazaga, MD, MBA, FAAD, FACMS, discusses Apex Dermatology's Purple Heart Project.

Germany will be the first country where lebrikizumab will be available for prescription, with a subsequent rollout across European countries throughout 2024.